Proteflazide

Pharmacological properties

flavonoids, which are part of the preparation, have the ability to inhibit the replication of dna and rna viruses both in vitro and in vivo. during preclinical and clinical studies, the inhibitory activity of the drug against influenza viruses and acute respiratory infections, herpes viruses was revealed.

It has been proven that the mechanism of direct antiviral action is to suppress the synthesis of virus-specific enzymes - DNA polymerase and RNA polymerase, thymidine kinase, reverse transcriptase, neuraminidase and induction of the synthesis of endogenous interferon.

The drug protects the mucous membranes of the upper respiratory tract, normalizing local immunity (lactoferrin, sIgA and lysozyme).

When conducting studies it was found that the drug normalizes the synthesis of endogenous α- and γ-interferons to a physiologically active level, which increases the nonspecific resistance of the body to viral and bacterial infections.

Clinical studies have shown that, given the daily intake of the drug in accordance with age-related doses and patterns of use, the immune system does not refract: there is no inhibition of the synthesis of α- and γ-interferons. This property of Flavovir syrup helps to maintain a level of interferon sufficient for an adequate immune response of the body to an infectious pathogen. This allows you to use the drug for a long period if necessary.

The drug has antioxidant activity, inhibits free radical processes, thereby preventing the accumulation of lipid peroxidation products, enhancing the antioxidant status of cells, reduces intoxication, and helps to restore the body after an infection and adapt to adverse environmental conditions.

The drug is a modulator of apoptosis: it enhances the action of apoptosis-inducing factors, namely, activating caspase 9, which contributes to a more rapid elimination of virus-infected cells and the primary prevention of chronic diseases against latent viral infections.

Pharmacokinetics The active substances of the drug are rapidly absorbed from the digestive tract into the blood, reaching C_max 20 minutes after administration (in vivo studies). According to the available dynamics T_½ from blood plasma is about 2.3 hours. Oral bioavailability is 80%. Excretion from the body is slow. The level of accumulation of active substances by blood cells compared with blood plasma is much higher. Appropriate concentrations of active substances provide a prolongation of the effect of the drug in the body and accumulation in organs and tissues as a result of their release from blood cells. Such available pharmacokinetic dynamics of the accumulation and release of active substances by blood cells necessitates a double dose of the drug during the day to achieve effective concentrations.

Indications

• Etiotropic treatment and prevention of ARVI; etiotropic treatment and prevention of influenza, including those caused by viruses of pandemic strains.

Application

Before use, the syrup bottle must be shaken.

The syrup should be dosed with a dosing container and taken orally 20-30 minutes before meals. To achieve a greater therapeutic effect in contact with respiratory viruses, it is advisable to delay the syrup for 20-30 seconds in the mouth by rinsing the throat before swallowing.

Doses and duration of treatment depend on the nature of the disease and the age of the patient.

Dosage schedule (ml) and frequency of administration of the drug

For the treatment of influenza and acute respiratory viral infections (with uncomplicated course of the disease), the syrup is used for 5 days. To achieve the greatest effectiveness of therapy, the use of syrup must be started at the first manifestations of the disease or after contact with patients. Depending on the course of the disease, the course of treatment can be extended up to 2 weeks.

For the prevention of influenza and acute respiratory viral infections, syrup is used for 1–4 weeks at a dose of half the therapeutic dose.

During an epidemic caused by pandemic strains, the duration of the use of a syrup in a prophylactic dose can be extended to 6 weeks.

In case of bacterial complications of influenza and other acute respiratory viral infections, in order to normalize the immune system, the syrup can be used for 4 weeks or longer.

Contraindications

• Hypersensitivity to the components of the drug; peptic ulcer of the stomach or duodenum in the acute stage; autoimmune diseases.

Side effects

Allergic reactions: in patients with hypersensitivity, hypersensitivity reactions are possible. allergic reactions may occur, including rash, itching, urticaria, and flushing of the skin.

From the digestive system: there are cases of gastrointestinal upsets - pain in the epigastric region, nausea, vomiting, diarrhea (in the presence of these symptoms, it is necessary to take syrup 1.5–2 hours after eating). In patients with chronic gastroduodenitis, gastroduodenitis may be exacerbated.